A Multicenter, Double-blind, Randomized, Parallel-group, Pilot Study of 12-week Duration to Assess the Short-term Safety and Tolerability of Lorcaserin Plus Two Doses of Immediate-Release Phentermine-HCl Compared With Lorcaserin Alone in Overweight and Obese Adults

Trial Profile

A Multicenter, Double-blind, Randomized, Parallel-group, Pilot Study of 12-week Duration to Assess the Short-term Safety and Tolerability of Lorcaserin Plus Two Doses of Immediate-Release Phentermine-HCl Compared With Lorcaserin Alone in Overweight and Obese Adults

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 May 2017

At a glance

  • Drugs Lorcaserin (Primary) ; Phentermine
  • Indications Obesity; Overweight
  • Focus Adverse reactions
  • Sponsors Eisai Inc
  • Most Recent Events

    • 01 May 2017 Results assessing the short-term safety and tolerability of combination therapy, published in the Obesity (Silver Spring, Md.)
    • 24 Sep 2015 Results will be presented at the 2015 Annual Meeting of the American College of Clinical Pharmacology, according to a GW Pharmaceuticals media release.
    • 17 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top